Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mangoceuticals, Inc. (MGRX : NSDQ)

• Company Description    Mangoceuticals Inc. is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc. is based in DALLAS, TX. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.52 Daily Weekly Monthly 20 Day Moving Average: 563,570 shares Shares Outstanding: 17.17 (millions) Market Capitalization: $8.94 (millions) Beta: 2.28 52 Week High: $2.75 52 Week Low: $0.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 40.81% 39.77% 12 Week 53.15% 48.95% Year To Date -29.64% -30.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 17130 DALLAS PKWY SUITE 240 - DALLAS,TX 75248 USA ph: 214-242-9619 fax: - investors@mangorx.com http://www.mangoceuticals.com

• General Corporate Information    Officers Jacob D. Cohen - Chief Executive Officer and Chairman Amanda Hammer - Chief Operating Officer Eugene M. Johnston - Chief Financial Officer Lorraine D'Alessio - Director Alex P. Hamilton - Director Peer Information Mangoceuticals, Inc. (GSAC) Mangoceuticals, Inc. (CASIF) Mangoceuticals, Inc. (ALCD.) Mangoceuticals, Inc. (OMNN) Mangoceuticals, Inc. (CGPI.) Mangoceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 56270V205 SIC: 8090 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 17.17 Most Recent Split Date: 10.00 (0.07:1) Beta: 2.28 Market Capitalization: $8.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.66 Price/Cash Flow: - Price / Sales: 21.59 EPS Growth vs. Year Ago Period: 82.95% vs. Previous Quarter: -269.23% Sales Growth vs. Year Ago Period: -37.61% vs. Previous Quarter: -27.66% ROE 06/30/26 - - 03/31/26 - -112.00 12/31/25 - -109.38 ROA 06/30/26 - - 03/31/26 - -104.96 12/31/25 - -102.40 Current Ratio 06/30/26 - - 03/31/26 - 0.29 12/31/25 - 1.74 Quick Ratio 06/30/26 - - 03/31/26 - 0.29 12/31/25 - 1.74 Operating Margin 06/30/26 - - 03/31/26 - -4,304.59 12/31/25 - -4,232.31 Net Margin 06/30/26 - - 03/31/26 - -4,639.13 12/31/25 - -4,536.70 Pre-Tax Margin 06/30/26 - - 03/31/26 - -4,639.37 12/31/25 - -4,526.97 Book Value 06/30/26 - - 03/31/26 - 0.79 12/31/25 - 0.93 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©